pentazirinocyclodiphosphathiazene has been researched along with Thrombopenia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mulder, NH; Rodenhuis, S; Schraffordt Koops, H; Sleijfer, DT; Van de Grampel, JC | 1 |
| Koops, HS; Mulder, NH; Rodenhuis, S; Sleijfer, DT; van de Grampel, JC | 1 |
| Carpentier, Y; Cattan, A; Coninx, P; Garbe, E; Jezekova, D; Nasca, S | 1 |
3 other study(ies) available for pentazirinocyclodiphosphathiazene and Thrombopenia
| Article | Year |
|---|---|
Phase I evaluation of SOAz (1,3,3,5,5 pentakis(aziridino)-1 lambda 6, 2,4,6,3 lambda 5, 5 lambda 5 thiatriaza-diphosphorine-1-oxide) in a weekly schedule.
Topics: Adult; Aged; Antineoplastic Agents; Azirines; Bone Marrow Diseases; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasms; Thrombocytopenia | 1984 |
Phase I clinical trial of (NPAz2)2NSOAz: 'SOAz'.
Topics: Adult; Aged; Antineoplastic Agents; Azirines; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Leukocyte Count; Leukopenia; Male; Middle Aged; Neoplasms; Platelet Count; Thrombocytopenia | 1983 |
Phase I study of SOAz.
Topics: Adult; Aged; Antineoplastic Agents; Azirines; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia | 1982 |